---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-004837"
form_type: "8-K"
ticker: null
cik: "0001442999"
company_name: "ALTEROLA BIOTECH INC."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T12:33:43.688581+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alterola sells Phytanix to Protagenic, plans to deregister; directors resign

## Summary
- Alterola and EMC2 sold 100% of Phytanix to Protagenic for Protagenic common and preferred stock; combined ownership: 35% existing Protagenic, 65% Alterola/EMC2.
- Alterola shareholders will be offered the option to swap ABTI shares for Protagenic shares; shareholder vote required by September 1, 2025.
- Alterola intends to terminate SEC registration and become a privately held company to reduce costs.
- Executive Chairman Tim Rogers, CEO David Hitchcock, CFO Nathan Thompson, and three independent directors resigned; Dominic Schiller and Colin Stott remain.

## SEC filing metadata
- accession: 0001477932-25-004837
- form_type: 8-K
- cik: 0001442999
- company_name: ALTEROLA BIOTECH INC.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/0001477932-25-004837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/abti_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-004837
- JSON: https://secwatch.observer/filing/0001477932-25-004837.json
- Plain text: https://secwatch.observer/filing/0001477932-25-004837.txt

## Key facts
- M&A Transactions
  ALTEROLA BIOTECH INC. completed a disposition involving Protagenic Therapeutics, Inc. for shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants (closed 2025-05-16).
  - Action: disposition
  - Counterparty: Protagenic Therapeutics, Inc.
  - Consideration: shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants
  - Closing: 2025-05-16
  source text: On May 16, 2025, Alterola, EMC2, and the Preferred Stockholders completed its business combination with Protagenic.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/0001477932-25-004837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.